Exelixis
EXEL
#1680
Rank
โ‚น858.35 B
Marketcap
โ‚น3,006
Share price
2.24%
Change (1 day)
67.33%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : โ‚น249.86 Billion

According to Exelixis's latest financial reports the company's total assets are โ‚น249.86 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚น244.94 B-3.63%
2022-12-31โ‚น254.16 B30.52%
2021-12-31โ‚น194.72 B24.58%
2020-12-31โ‚น156.31 B16.24%
2019-12-31โ‚น134.46 B35.21%
2018-12-31โ‚น99.44 B137.68%
2017-12-31โ‚น41.84 B3.35%
2016-12-31โ‚น40.48 B83.3%
2015-12-31โ‚น22.08 B7.8%
2014-12-31โ‚น20.48 B-34.11%
2013-12-31โ‚น31.09 B-21.25%
2012-12-31โ‚น39.48 B89.79%
2011-12-31โ‚น20.80 B28.68%
2010-12-31โ‚น16.16 B1.46%
2009-12-31โ‚น15.93 B-17.46%
2008-12-31โ‚น19.30 B19.35%
2007-12-31โ‚น16.17 B-7.65%
2006-12-31โ‚น17.51 B16.97%
2005-12-31โ‚น14.97 B18.66%
2004-12-31โ‚น12.61 B-22.55%
2003-12-31โ‚น16.29 B0.17%
2002-12-31โ‚น16.26 B-2.77%
2001-12-31โ‚น16.72 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚น6.557 T 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น11.740 T 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น9.920 T 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.906 T 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.670 T 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น15.048 T 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น18.524 T 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.25 B-98.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น8.54 B-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA